Skip to article
Astra

Critical Care

Neurogenic Shock

Neurogenic shock is acute distributive shock after high spinal cord injury, driven by loss of sympathetic tone and often accompanied by bradycardia. Immediate priorities are trauma resuscitation, exclusion of hemorrhage and other shock states, invasive hemodynamic monitoring, and blood-pressure augmentation while definitive spinal evaluation proceeds.

Clinical question: How should clinicians recognize and stabilize neurogenic shock after acute spinal cord injury?

Clinical phenotype

Recognize the hemodynamic syndrome and localize the lesion

Treat shock immediately while defining its mechanism.

Neurogenic shock follows acute disruption of sympathetic pathways, classically from spinal cord pathology above T6. The resulting loss of sympathetic tone below the lesion lowers vascular tone and can produce hypotension. In acute spinal cord injury, disconnected sympathetic innervation is associated with decreased heart rate, blood pressure, cardiac output, and systemic vascular resistance. Wolters KluwerSpinal Cord Anatomy and Localization | ContinuumWolters KluwerSpine : Operative Neurosurgery

The bedside pattern of hypotension with inappropriately low or reduced heart rate after cervical or high thoracic spinal cord injury should raise suspicion, but it should not close the diagnostic evaluation. Trauma-associated hypotension requires parallel assessment for bleeding, mechanical obstruction, myocardial dysfunction, drug effects, and sepsis when clinically plausible.

Hemodynamic implications of acute spinal cord injury Wolters KluwerSpinal Cord Anatomy and Localization | ContinuumWolters KluwerSpine : Operative Neurosurgery
FindingClinical implication
Injury above T6Loss of sympathetic tone below the lesion can cause hypotension. Wolters KluwerSpinal Cord Anatomy and Localization | Continuum
Bradycardia or low-normal heart rate during hypotensionSupports impaired sympathetic cardiac response; assess for other contributors and treat unstable bradycardia according to the clinical context. Wolters KluwerSpine : Operative Neurosurgery
Low cardiac output and systemic vascular resistanceSupports a distributive hemodynamic phenotype and need for monitored resuscitation and vasopressor-based support when hypotension persists. Wolters KluwerSpine : Operative Neurosurgery

First hours

Stabilize in a monitored critical-care setting

Prevent secondary spinal cord ischemia while maintaining trauma priorities.

Patients with suspected neurogenic shock after acute spinal cord injury require close hemodynamic monitoring in an ICU-level setting. A neurosurgical review describes arterial-line consideration and ICU admission to ensure blood-pressure stability during the immediate period after injury. Wolters KluwerSpine : Operative Neurosurgery

Initial care should proceed as trauma resuscitation: secure oxygenation and ventilation, protect the spine, establish reliable vascular access, identify and control hemorrhage, and reassess perfusion after each intervention. Do not attribute refractory hypotension solely to neurogenic shock until hemorrhage and other immediately reversible causes have been actively considered.

Fluid administration may be necessary when hypovolemia is present, but persistent vasodilatory hypotension should prompt vasopressor support rather than repeated unbounded fluid loading. This distinction is especially important when reduced cardiac output, pulmonary complications, or concomitant injury limits fluid tolerance.

  • Continuous ECG, frequent blood-pressure measurement, serial neurologic examinations, urine output, and repeated assessment of peripheral perfusion are appropriate during active shock management.

  • Consider an arterial catheter when continuous blood-pressure targeting or frequent blood sampling is needed; this is specifically noted as potentially warranted in acute spinal cord injury care. Wolters KluwerSpine : Operative Neurosurgery

  • Involve spine surgery or neurosurgery early for unstable injury, cord compression, or a lesion requiring decompression or fixation.

Early bedside priorities in suspected neurogenic shock
PriorityActionReason
Spinal protectionMaintain immobilization appropriate to the suspected level of injury and obtain urgent spinal evaluation.Further displacement or unrecognized compression may worsen neurologic injury.
Competing shock causesConduct repeated trauma-focused evaluation for hemorrhage and evaluate other shock mechanisms as indicated.Neurogenic shock can coexist with hemorrhage or cardiopulmonary injury.
Hemodynamic surveillanceUse ICU-level monitoring; consider an arterial line when needed for MAP-directed management. Wolters KluwerSpine : Operative NeurosurgeryRapid recognition of hypotension and bradycardia supports timely escalation.

Hemodynamic strategy

Use MAP augmentation selectively and document the evidence limits

Targeting is intended to support cord perfusion during the acute injury phase.

A neurosurgical review describes medical management of acute spinal cord injury with MAP augmentation above 85 mm Hg for 3 to 7 days. Wolters KluwerSpine : Operative Neurosurgery This target should be individualized to the injury pattern, concurrent bleeding, cardiac function, arrhythmia risk, and the ability to provide invasive monitoring. The supplied search results do not provide a current formal U.S. guideline recommendation, comparative vasopressor trial data, or an evidence-based lower or upper duration threshold.

Avoid interpreting a MAP goal as a substitute for source control of bleeding, decompression when indicated, respiratory support, or definitive stabilization of the spinal injury. Reassess the need for pressors continuously as vasoplegia and bradycardia evolve.

  • Document baseline and achieved MAP, vasopressor dose, heart-rate trend, perfusion markers, and complications during MAP augmentation.

  • Escalate evaluation if hypotension remains disproportionate to the neurologic lesion or is accompanied by evidence of blood loss, hypoxemia, chest injury, ischemic ECG changes, or new ventricular dysfunction.

  • The supplied sources support a commonly used MAP strategy but do not establish an optimal vasopressor, exact titration protocol, or outcome benefit for every acute spinal cord injury phenotype.

Blood-pressure support statements available from supplied sources
InterventionAvailable supportPractical limitation
MAP augmentationMAP greater than 85 mm Hg for 3 to 7 days is described in a neurosurgical review of acute spinal cord injury management. Wolters KluwerSpine : Operative NeurosurgeryThe supplied evidence does not provide a contemporary guideline grade, individualized target framework, or comparative efficacy data.
Norepinephrine or dopamineThe review identifies dopamine or norepinephrine for MAP augmentation in this setting. Wolters KluwerSpine : Operative NeurosurgeryNo dosing, comparative outcomes, or selection algorithm is provided in the supplied result.
PhenylephrineThe review advises dopamine or norepinephrine rather than phenylephrine because phenylephrine can cause reflex bradycardia in neurogenic shock. Wolters KluwerSpine : Operative NeurosurgeryThis is source-specific expert guidance; individual use requires hemodynamic and rhythm assessment.

Pharmacology

Select vasoactive therapy by vasoplegia, chronotropy, and safety

Evidence supplied here supports principles more clearly than a definitive drug hierarchy.

For acute spinal cord injury with neurogenic shock, dopamine or norepinephrine are described as agents for MAP augmentation, with a specific caution that phenylephrine can precipitate reflex bradycardia. Wolters KluwerSpine : Operative Neurosurgery In practice, selection should account for the degree of bradycardia, ventricular function, arrhythmia susceptibility, and the need for predominantly vasoconstrictor versus combined inotropic and chronotropic effects.

Angiotensin II is FDA-labeled as a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock. The DailyMed label recommends a starting dose of 20 ng/kg/min by continuous IV infusion. dailymed nlm nihLabel: GIAPREZA- angiotensin ii injection - DailyMeddailymed nlm nihLabel: ANGIOTENSIN II injection - DailyMed Neurogenic shock is a distributive state, but the supplied sources do not establish efficacy, safety, or a preferred place for angiotensin II in this specific condition; using it for neurogenic shock should therefore be considered off-label.

Vasoactive agents referenced in supplied sources
AgentSource-supported roleKey selection issue
NorepinephrineOption for MAP augmentation in acute spinal cord injury. Wolters KluwerSpine : Operative NeurosurgerySupplied sources do not provide dose or comparative outcomes.
DopamineOption for MAP augmentation in acute spinal cord injury. Wolters KluwerSpine : Operative NeurosurgerySupplied sources do not provide dose or comparative outcomes.
PhenylephrineNot favored over dopamine or norepinephrine in the cited review. Wolters KluwerSpine : Operative NeurosurgeryMay cause reflex bradycardia in neurogenic shock. Wolters KluwerSpine : Operative Neurosurgery
Angiotensin IIFDA-labeled vasoconstrictor for adults with septic or other distributive shock; start 20 ng/kg/min by continuous IV infusion. dailymed nlm nihLabel: GIAPREZA- angiotensin ii injection - DailyMeddailymed nlm nihLabel: ANGIOTENSIN II injection - DailyMedSpecific neurogenic-shock evidence is absent in the supplied results; use would be off-label.

Concurrent management

Pair hemodynamic rescue with injury-directed care and complication prevention

Shock management cannot be separated from definitive spinal cord injury care.

After physiologic stabilization, urgent characterization of cord compression, instability, and associated injuries directs operative and nonoperative management. The supplied sources note early decompression for cauda equina compression and emphasize critical-care admission after acute spinal injury to maintain blood-pressure stability. Wolters KluwerSpine : Operative Neurosurgery They do not provide sufficient evidence to specify decompression timing or operative indications for every spinal injury pattern.

The same review describes supportive elements of acute spinal cord injury care, including lower-extremity compression, abdominal binder use to improve MAP, cough assistance, nutritional support, ulcer prophylaxis, rehabilitation consultation, and early mobilization. Wolters KluwerSpine : Operative Neurosurgery Apply these measures according to injury pattern, contraindications, respiratory status, and institutional protocols.

  • Assess and manage respiratory compromise aggressively, particularly with cervical injury.

  • Initiate early multidisciplinary planning involving critical care, spine surgery or neurosurgery, trauma, rehabilitation, nursing, and respiratory therapy.

  • Monitor for complications of immobilization and spinal cord injury, including venous thromboembolism, pulmonary complications, ileus, pressure injury, and urinary dysfunction; the supplied review identifies preventive supportive strategies but does not provide regimen-level details. Wolters KluwerSpine : Operative Neurosurgery

Supportive measures described for acute spinal cord injury Wolters KluwerSpine : Operative Neurosurgery
MeasureIntended purpose
Lower-extremity compression stockingsReduce risk of deep vein thrombosis and pulmonary embolism. Wolters KluwerSpine : Operative Neurosurgery
Abdominal binderImprove MAP. Wolters KluwerSpine : Operative Neurosurgery
Cough assistanceReduce risk of pneumonia. Wolters KluwerSpine : Operative Neurosurgery
Early mobilization and rehabilitation consultationSupport recovery and reduce complications of immobility. Wolters KluwerSpine : Operative Neurosurgery

Common questions

What finding most strongly suggests neurogenic rather than hemorrhagic shock after spinal trauma?

Hypotension with bradycardia or an inappropriately absent tachycardic response after cervical or high thoracic cord injury supports neurogenic shock, reflecting loss of sympathetic tone. However, bleeding must still be actively excluded because shock mechanisms may coexist. Wolters KluwerSpinal Cord Anatomy and Localization | ContinuumWolters KluwerSpine : Operative Neurosurgery

What MAP target is used in acute spinal cord injury with neurogenic shock?

A neurosurgical review describes augmenting MAP above 85 mm Hg for 3 to 7 days in acute spinal cord injury. Wolters KluwerSpine : Operative Neurosurgery The supplied search results do not establish a universally optimal target, duration, or patient-specific escalation threshold.

Which vasopressor is preferred in neurogenic shock?

The supplied review identifies norepinephrine or dopamine for MAP augmentation and advises them over phenylephrine because phenylephrine may cause reflex bradycardia. Wolters KluwerSpine : Operative Neurosurgery It does not provide comparative trial evidence or dosing to establish a universal first-line agent.

Is angiotensin II indicated for neurogenic shock?

Angiotensin II is FDA-labeled for adults with septic or other distributive shock, with a recommended initial continuous infusion of 20 ng/kg/min. dailymed nlm nihLabel: GIAPREZA- angiotensin ii injection - DailyMeddailymed nlm nihLabel: ANGIOTENSIN II injection - DailyMed The supplied sources do not establish its role in neurogenic shock; use for that indication is off-label.

References

  1. Label: GIAPREZA- angiotensin ii injection - DailyMeddailymed.nlm.nih.gov · dailymed.nlm.nih.gov
  2. Maxipime for Injection - accessdata.fda.govwww.accessdata.fda.gov · www.accessdata.fda.gov
  3. 214787Orig1s010 - accessdata.fda.govwww.accessdata.fda.gov · www.accessdata.fda.gov
  4. FDA Adverse Event Reporting System Freedom of Information ...www.accessdata.fda.gov · www.accessdata.fda.gov
  5. 2021 First Generic Drug Approvals | FDAwww.fda.gov · www.fda.gov
  6. Label: ANGIOTENSIN II injection - DailyMeddailymed.nlm.nih.gov · dailymed.nlm.nih.gov
  7. 022569Orig1s000 - accessdata.fda.govwww.accessdata.fda.gov · www.accessdata.fda.gov
  8. PRAMIPEXOLE DIHYDROCHLORIDE 0.125 mg, 0.25 mg, 0.5 mg, 1 mg, and 1.5 mg Tabletsdailymed.nlm.nih.gov · dailymed.nlm.nih.gov
  9. CLINICAL REVIEWwww.fda.gov · www.fda.gov
  10. Subject:www.fda.gov · www.fda.gov
  11. Efficacy and safety of phospholipid nanoparticles (VBI-S) in ...www.thelancet.com · www.thelancet.com
  12. 2017 ACC/AHA/HRS Guideline for the Evaluation and ...www.jacc.org · www.jacc.org
  13. Stress Cardiomyopathy Diagnosis and Treatment: JACC State-of-the-Art Reviewwww.jacc.org · www.jacc.org
  14. 2023 Guideline for the Management of Patients With ...www.ahajournals.org · www.ahajournals.org
  15. 2023 ACC Expert Consensus Decision Pathway on ...www.jacc.org · www.jacc.org
  16. Current Concepts on the Management of Shock | Circulationwww.ahajournals.org · www.ahajournals.org
  17. A prospective evaluation of hemodynamic management in ...www.nature.com · www.nature.com
  18. Modeling trajectories of routine blood tests as dynamic biomarkers for outcome in spinal cord injurywww.nature.com · www.nature.com
  19. Hyponatremia in spinal cord injury patients: new insight ...www.nature.com · www.nature.com
  20. Spinal cord injury: molecular mechanisms and therapeutic interventions | Signal Transduction and Targeted Therapywww.nature.com · www.nature.com
  21. Spinal Cord Anatomy and Localization | Continuumjournals.lww.com · journals.lww.com
  22. Key Points for Issue | Continuumjournals.lww.com · journals.lww.com
  23. Spine : Operative Neurosurgeryjournals.lww.com · journals.lww.com
  24. Urogenital Symptoms in Neurologic Patientsjournals.lww.com · journals.lww.com